Treatment of hormone-refractory carcinoma of the prostate with mitoxantrone;DIE THERAPIE DES HORMONREFRAKTAREN PROSTATAKARZINOMS MIT MITOXANTRON

Urologe - Ausgabe A

Volumn 35, Issue 2, 1996, Pages 142-145

  Otto, T ^a   Rembrink, K ^a   Goepel, M ^a   Krege, S ^a   Meyer Schwickerath, M ^b   Rubben H ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Urologische Abteilung   (Germany)

Author keywords

chemotherapy; hormone refractory carcinoma; prostate cancer; supportive care; symptomatic tumor progress

Indexed keywords

ALKALINE PHOSPHATASE; MITOXANTRONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; FOLLOW UP; HORMONE RESISTANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NAUSEA; NEPHROTOXICITY; PROSTATE CARCINOMA; THROMBOCYTOPENIA; VOMITING;

EID: 0029871132     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Altwein JE, Wirth MP (1994) Prostatakarzinom. In: Rübben (Hrsg) Uroonkologie. Springer. Berlin Heidelberg New York, S 230-231
2. Chlebowski RT, Herstorff R, Sardoff L, Bateman JR (1978) Cyclophosphamide versus the combination of cyclophosphamide, ADM, 5-FU in the treatment of metastatic prostatic cancer. Cancer 42: 2546-2552
3. Eagan RT, Hahn RG, Myers RR (1976) ADM versus 5-FU and cyclophosphamide in the treatment of advanced prostatic cancer. Cancer Treat Rep 60: 115-117
4. Muss HB, Hovard V, Richards F (1981) Cyclophosphamide versus cyclophosphamide, MTX, 5-FU in advanced prostatic cancer. Cancer 47: 1949-1954
5. Tubiana M, Malaise P (1976) Growth rate and cell kinetics in human tumors: some prognostic and therapeutic implications. In: Symington. Carter (eds) Scientific foundations of oncology. Heinemann, London, pp 126-135
6. Wirth MP (1990) Wertigkeit der Chemotherapie in der Behandlung des fortgeschrittenen Prostatakarzinoms. In: Frohmüller, Wirth (Hrsg) Behandlung des fortgeschrittenen Prostatakarzinoms, 14. Aufl. Springer. Berlin Heidelberg New York, S 16-21